Clinical effect of capecitabine combined with oxaliplatin on patients with stage Ⅲ colorectal cancer and its impact to immune function and quality of life
10.3760/cma.j.issn.1008-6706.2017.17.002
- VernacularTitle:卡培他滨联合奥沙利铂治疗Ⅲ期结直肠癌疗效及对患者免疫功能、生活质量的影响
- Author:
Yongping LIU
- Keywords:
Capecitabine;
Oxaliplatin;
Colorectal neoplasms
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(17):2566-2569
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore clinical effect of capecitabine combined with oxaliplatin on stage Ⅲ colorectal cancer,as well as its impact to immune function and quality of life.Methods 62 cases with stage Ⅲ colorectal cancer were selected as research subjects,and they were randomly divided into control group (oxaliplatin combined with 5-fluorouracil + calcium folinate,FOLFOX4 plan) and observation group (capecitabine combined with oxaliplatin,XELOX plan),31 cases in each group.The clinical effect,immune function and quality of life were compared between the two groups.Results The total effective rate had no obvious difference between the two groups(P＞0.05).The levels of CD+3,CD+4 and CD+8 cells of the observation group were (68.31±6.37)％,(43.58±4.24)％,(46.35±5.34)％,respectively,which of the control group were (57.72±5.26)％,(35.28±5.21)％,(38.76±4.42)％,respectively.After treatment,the above indicators of the two groups were significantly higher than those before treatment,which of the observation group were significantly higher than those of the control group(t=15.09,6.88,7.14,all P＜0.05).After treatment,the scores of emotion,role,social,physical,cognition and total scores of the observation group were (84.38±3.02)points,(82.36±3.03)points,(63.35±3.08)points,(89.24±4.05)points,(90.14±4.02)points,(69.53±4.28)points,respectively,which of the control group were (76.91±4.04)points,(73.82±3.07)points,(56.83±3.11)points,(86.42±4.04)points,(85.52±3.06)points,(54.49±4.32)points,respectively.After treatment,the scores of the two groups were significantly higher than those before treatment,which of the observation group were significantly higher than those of the control group (t=8.25,11.02,8.29,2.75,5.09,13.77,all P＜0.05).Conclusion Capecitabine combined with oxaliplatin has similar clinical effect with routine FOLFOX4 plan on patients with stage Ⅲ colorectal cancer,and it can help patients to improve immune cell function and quality of life,so it is worthy to be promoted in clinical.
